Study on Acalabrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients Without del(17p) or TP53 Mutation

This clinical trial is focused on studying the effectiveness and safety of a new treatment approach for people with Chronic Lymphocytic Leukemia (CLL), a type of cancer that affects the blood and bone marrow. The study involves a combination of medications, including an investigational drug called acalabrutinib (also known as ACP-196), and two other drugs, venetoclax and obinutuzumab. These medications will be compared to standard chemotherapy treatments that are commonly used for CLL, such as combinations involving fludarabine, cyclophosphamide, and rituximab, or bendamustine and rituximab.

The purpose of this study is to evaluate how well the new combination of acalabrutinib, venetoclax, and obinutuzumab works compared to the traditional chemotherapy options. Participants in the study will be randomly assigned to receive either the new combination treatment or one of the standard chemotherapy treatments. The study will monitor participants over a period of time to assess the progression of the disease and any side effects experienced. The medications will be administered either orally or through intravenous infusion, depending on the specific drug.

This trial is designed for individuals who have not received prior treatment for their CLL and do not have certain genetic mutations, specifically the del(17p) or TP53 mutation. The study aims to provide valuable information on whether the new treatment combination can offer better outcomes for patients with CLL compared to existing chemotherapy options. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and to gather data on the effectiveness of the treatments.